Haematological Malignancies, Leukaemia
Molecular Monitoring of BCR-ABL Transcripts—Standardization Needed to Properly Use, and Further Investigate the Value of, a Critical Surrogate Marker for Success in Therapy of Chronic Myeloid Leukemia
Francis J Giles
Chronic myeloid leukemia (CML) is a progressive and potentially fatal myeloproliferative disorder with over 5,000 new cases in the US each year, accounting for approximately 20 % of all leukemias diagnosed in adults.1 The natural history of CML consists of three distinct stages: chronic, accelerated, and blast phase.2 Most patients (90 %) are diagnosed in […]